Traws Pharma, Inc.

Overview

Compare with Upstream Bio, Inc., Xenetic Biosciences (United States) or TherapeuticsMD, Inc., or pick any stock.

• TickerTRAW on Nasdaq²
• IndustryPharmaceutical Preparations²
• HeadquartersNewtown, United States²
• Incorporated inDE³
• Business address12 Penns Trail, Newtown, Pa 18940³
• Filer categoryNon-accelerated filer, Smaller reporting company³
• Legal formCorporation²
• LEI549300BRAR7BTG2PIY51²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 2983483²

See how the biggest companies compare on our leaderboards

Traws Pharma, Inc. (“Traws,” “we,” or the “Company”) is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. We are advancing novel investigational antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health. Our product candidates are intended to be safe, with simple dosing regimens. We strive to utilize accelerated clinical trial strategies with a commitment to patients who are especially vulnerable.⁴ From its latest annual report

Corporate structure

Traws Pharma, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Traws Pharma, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Intangibles and goodwill

Properties, in its own words

Our corporate headquarters is located in Newtown, Pennsylvania, where we lease short-term flexible office space. We believe that suitable additional or alternative space would be available on commercially reasonable terms if required in the future.

Item 2 of the 10-K filed Apr 15, 2026.⁴

Leadership

Who has led Traws Pharma, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerIain D. Dukes Oct 15, 2025 to now¹⁴
• Chief executive officerWerner Cautreels Apr 3, 2024 to Oct 15, 2025¹⁵
• Chief executive officerSteven M. Fruchtman Nov 26, 2019 to Mar 15, 2024¹⁶
• Chief executive officerRamesh Kumar Jul 24, 2013 to Jul 30, 2018¹⁷
• ChairIain D. Dukes Apr 3, 2024 to Aug 7, 2024¹⁸
• PresidentSteven M. Fruchtman Jul 30, 2018 to Mar 15, 2024¹⁹
• PresidentRamesh Kumar Jul 24, 2013 to Feb 27, 2018¹⁷
• PresidentThomas J. McKearn Jul 24, 2013 to Jan 28, 2016²⁰
• Chief financial officerCharles Nolan Parker Apr 8, 2026 to now²¹
• Chief financial officerNora Brennan Feb 7, 2025 to Apr 8, 2026²²
• Chief financial officerMark Patrick Guerin Sep 1, 2016 to Feb 7, 2025²³
• Chief financial officerAjay Bansal Jul 24, 2013 to Jan 28, 2016²⁴
• Chief operating officerNikolay Savchuk Apr 3, 2024 to now²⁵
• Chief operating officerMark Patrick Guerin Jun 13, 2022 to Mar 15, 2024²⁶

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Chief Scientific Officer, VirologyDavid Pauza named Apr 16, 2024⁴⁸
• DirectorIan Dukes named Apr 16, 2024⁴⁸
• DirectorM. Theresa Shoemaker named Apr 16, 2024⁴⁸

Former names

• Onconova Therapeutics, Inc.Mar 4, 2010 to Apr 1, 2024³
• ONCONOVA THERAPEUTICS INCJan 8, 2003 to May 26, 2009³

Timeline

1. Aug 14, 20268-K Results of operations; Regulation FD disclosure⁴⁹
2. Jul 31, 20268-K Listing notice or transfer⁵⁰
3. Jul 10, 20268-K Other events⁵¹
4. Jul 9, 20268-K Executive or director change; Shareholder vote⁵²
5. Jun 22, 20268-K Regulation FD disclosure⁵³
6. Jun 12, 20268-K Regulation FD disclosure⁵⁴
7. May 27, 20268-K Regulation FD disclosure⁵⁵
8. May 26, 20268-K Other events⁵⁶
9. May 15, 20268-K Results of operations; Regulation FD disclosure⁵⁷
10. Apr 15, 20268-K Entered a material agreement; Unregistered sale of shares; Other events⁵⁸
11. Apr 15, 20268-K Results of operations; Regulation FD disclosure⁵⁹
12. Feb 19, 20268-K Other events⁶⁰
13. Oct 15, 2025New chief executive Iain D. Dukes becomes CEO¹⁴
14. Apr 3, 2024New chief executive Werner Cautreels becomes CEO¹⁵
15. Nov 26, 2019New chief executive Steven M. Fruchtman becomes CEO¹⁶
16. Jul 24, 2013New chief executive Ramesh Kumar becomes CEO¹⁷
17. Dec 22, 1998Founded Traws Pharma, Inc. is founded²

Calendar

Coming up

1. Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.34) a share, on Nov 13, 2025.⁶¹

When it reported results

1. Aug 14, 2026Reported quarterly or annual results⁴⁹
2. May 15, 2026Reported quarterly or annual results⁵⁷
3. Apr 15, 2026Reported quarterly or annual results⁵⁹
4. Nov 13, 2025Reported quarterly or annual results⁶²
5. Aug 14, 2025Reported quarterly or annual results⁶³
6. May 15, 2025Reported quarterly or annual results⁶⁴
7. Mar 31, 2025Reported quarterly or annual results⁶⁵
8. Nov 14, 2024Reported quarterly or annual results⁶⁶

Drug trials and FDA: coming up

1. Nov 2026Phase 2 trial readout expected Phase 2 trial of TRX-100 and Influenza A/France/759/2021 (H1N1) virus in Influenza: primary completion expected Nov 2026 (ClinicalTrials.gov NCT07503405).⁶⁷
2. Dec 2026Phase 2 trial readout expected Phase 2 trial of TRX-100 and Standard of Care (SOC) in Influenza: primary completion expected Dec 2026 (ClinicalTrials.gov NCT07371650).⁶⁸

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

318 filings to the SEC since October 2021: 10 annual reports, 15 quarterly reports, 82 major events, 120 insider forms, 29 large holders, 1 private raises, 61 other. The latest 20:

1. Oct 8, 2026PRE 14A EDGAR
2. Aug 14, 2026SCHEDULE 13G/A EDGAR
3. Aug 14, 2026SCHEDULE 13G/A EDGAR
4. Aug 14, 202610-Q EDGAR
5. Aug 14, 20268-K EDGAR
6. Aug 14, 2026SCHEDULE 13G EDGAR
7. Aug 12, 2026SCHEDULE 13G/A EDGAR
8. Jul 31, 20268-K EDGAR
9. Jul 16, 20264 EDGAR
10. Jul 15, 20264 EDGAR
11. Jul 15, 20264 EDGAR
12. Jul 14, 20264 EDGAR
13. Jul 14, 20264 EDGAR
14. Jul 14, 20264 EDGAR
15. Jul 14, 20264 EDGAR
16. Jul 14, 20264 EDGAR
17. Jul 14, 20264 EDGAR
18. Jul 14, 20264 EDGAR
19. Jul 10, 20268-K EDGAR
20. Jul 10, 2026424B5 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

6 open-market trades by officers, directors and large owners since October 2021: 6 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Ikarian Capital, LLCSCHEDULE 13G/A, 4 filings Feb 14, 2025 to Aug 14, 2026⁶⁹
• Sirenia Capital Management LPSCHEDULE 13G, 1 filing Aug 14, 2026⁷⁰
• Squadron Capital Management LLCSCHEDULE 13G/A, 5 filings Sep 19, 2025 to Aug 14, 2026⁷¹
• Adage Capital Management, L.P.SCHEDULE 13G/A, 4 filings May 12, 2025 to Aug 12, 2026⁷²
• PERCEPTIVE ADVISORS LLCSCHEDULE 13G/A, 4 filings Jan 8, 2025 to May 15, 2026⁷³
• ORBIMED ADVISORS LLCSCHEDULE 13D/A, 4 filings Sep 23, 2024 to May 5, 2026⁷⁴
• Ayrton Capital LLCSCHEDULE 13G/A, 2 filings Feb 13, 2025 to Feb 11, 2026⁷⁵
• Jorey ChernettSCHEDULE 13G, 1 filing Jan 16, 2026⁷⁶
• Alyeska Investment Group, L.P.SCHEDULE 13G, 1 filing Feb 14, 2025⁷⁷
• Viriom, Inc.SC 13D, 1 filing Apr 8, 2024⁷⁸
• CVI Investments, Inc.SC 13G/A, 2 filings Oct 1, 2021 to Feb 14, 2022⁷⁹

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Apr 1, 2024Raised $14 million in a private offering of securities⁴⁸ Form D: 2 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 34. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Traws Pharma, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARTraws Pharma, Inc.¹
• CIK0001130598
• Employer ID (EIN)22-3627252⁴
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company⁴
• Incorporated inDelaware⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address12 Penns Trail, Newtown, PA 18940¹
• Phone267-759-3680¹
• Shares outstanding15,368,277 as of Aug 12, 2026¹²
• Public float$9.8M as of Jun 30, 2025⁴
• AuditorKPMG LLP, Philadelphia, Pennsylvania PCAOB ID 185; no auditor attestation of internal control over financial reporting⁴
• On EDGAR sinceJan 8, 2003¹
• Filings984 in all: 4 (324), 8-K (223), 3 (42), 10-Q (40), CORRESP (29), DEFA14A (22), 424B5 (21), UPLOAD (20)¹
  All 49 form types

  SC 13G (19), DEF 14A (18), SC 13G/A (18), EFFECT (16), S-1/A (15), 10-K (13), 424B3 (13), SCHEDULE 13G/A (13), S-8 (11), PRE 14A (10), S-3 (9), SCHEDULE 13G (9), D (8), SC 13D/A (8), 10-K/A (7), REGDEX/A (7), 424B4 (6), ARS (6), S-1 (6), 3/A (5), REGDEX (5), SC 13D (5), 144 (3), 8-K/A (3), D/A (3), FWP (3), S-3/A (3), 4/A (2), 8-A12B (2), CERTNAS (2), CT ORDER (2), POS AM (2), SCHEDULE 13D/A (2), SEC STAFF LETTER (2), 25-NSE (1), 424B2 (1), DRS (1), NT 10-K (1), NT 10-Q (1), PRER14A (1), S-1MEF (1)

• Latest filingsAnnual report (10-K) Apr 15, 2026
  Quarterly report (10-Q) Aug 14, 2026
  Proxy statement (DEF 14A) May 29, 2026
  Latest 8-K (8-K) Aug 14, 2026

Securities registered for trading

From the cover page of the 10-K filed Apr 15, 2026 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks Traws Pharma, Inc. names in Item 1A of its 10-K filed Apr 15, 2026: 47 risks under these headings, as written.⁴

• Risks Related to Our Financial Position and Capital Needs
• Our recurring operating losses, negative cash flows from operations, and accumulated deficit raise substantial doubt about our ability to continue as a going concern absent obtaining adequate new financings.
• The report of our independent registered accounting firm on our audited financial statements for the fiscal year ended December 31, 2025 contains an explanatory paragraph relating to our ability to continue as a going concern.
• We need to obtain additional funding to execute our business plans; if we are unable to meet our needs for additional funding in the future, we will be required to limit, scale back or cease operations.
• We have incurred significant losses since our inception and anticipate that we will continue to incur losses in the future.
• We currently have no source of product revenue and may never become profitable.
• Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
• We maintain our cash at financial institutions, often in balances that exceed federally insured limits.
• We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability, including the ongoing military conflicts between Russia and Ukraine and Israel and Hamas and the recent military conflict in Iran. Our business, financial condition and results of operations could be materially adversely affected by any negative impact on the global economy and capital markets resulting from any such geopolitical tensions.
• International trade disputes have resulted in tariffs and other protectionist measures that could have a material adverse effect on our business, financial condition and results of operations.
• Changes in United States and China relations, as well as relations with other countries, and/or regulations may adversely impact our business, our operating results, our ability to raise capital and the market price of our shares.
• We may be adversely affected by the effects of inflation.

Legal proceedings

For a description of our material pending legal proceedings, please see Note 6, Commitments and Contingencies, to our consolidated financial statements included in Part IV in this Annual Report. We may, in the ordinary course of business, face various claims brought by third parties, and we may, from time to time, make claims or take legal actions to assert our rights, including intellectual property rights as well as claims relating to employment matters and the safety or efficacy of our products. Any of these claims could subject us to costly litigation. If this were to happen, the payment of any such awards could have a material adverse effect on our business, financial condition and results of operations. Additionally, any such claims, whether or not successful, could damage our reputation and business.

The opening of Item 3, Legal Proceedings.⁴